Emflaza

Chemical Namedeflazacort
Dosage FormTablet (oral; 6 mg, 18 mg, 30 mg, 36 mg); Suspension (oral; 22.75 mg/mL)
Drug ClassCorticosteroids
SystemMusculoskeletal
CompanyPTC Therapeutics
Approval Year2017

Indication

  • For the treatment of Duchenne muscular dystropy in patients ≥ 5 years of age
Last updated on 4/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Emflaza (deflazacort) Prescribing Information.2017PTC Therapeutics, Inc., South Plainfield, NJ
Document TitleYearSource
Corticosteroids for the treatment of Duchenne muscular dystrophy. 2016The Cochrane Database of Systematic Reviews